Attached files

file filename
EX-10.1 - EX-10.1 - ImmunityBio, Inc.d21044dex101.htm
EX-2.1 - EX-2.1 - ImmunityBio, Inc.d21044dex21.htm
8-K - 8-K - ImmunityBio, Inc.d21044d8k.htm

Exhibit 10.2

Execution Version

VOTING AGREEMENT

This VOTING AGREEMENT (this “Agreement”), dated as of December 21, 2020, is by and between NantKwest, Inc., a Delaware corporation (“Parent”), ImmunityBio, Inc., a Delaware corporation (the “Company”), and the Persons set forth on Schedule A (the “Company Significant Stockholders”).

WHEREAS, concurrently with the execution and delivery hereof, the Company, Parent and Nectarine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, have entered into an Agreement and Plan of Merger (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the “Merger Agreement”), which provides for, among other things, the merger of Merger Sub with and into the Company, with the Company being the surviving corporation (the “Merger”), as a result of which Merger the Company will become a wholly owned Subsidiary of Parent, subject to the conditions set forth in the Merger Agreement (capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement);

WHEREAS, the affirmative vote of holders of a majority of the outstanding Company Shares is the only vote of the holders of the Company’s capital stock necessary to adopt the Merger Agreement and approve the Merger;

WHEREAS, as of the date hereof, each Company Significant Stockholder, is the record or beneficial owner of the number of Company Shares set forth opposite such Company Significant Stockholder’s name on Schedule A (such Company Shares, together with any other Company Shares acquired by such Company Significant Stockholder after the date hereof and during the term of this Agreement, being collectively referred to as the “Subject Shares” of such Company Significant Stockholder); and

WHEREAS, as a condition to its willingness to enter into the Merger Agreement, the Company and Parent have required that the Company Significant Stockholders, and as an inducement and in consideration therefor, the Company Significant Stockholders (in each Company Significant Stockholder’s capacity as a holder of Company Shares) has agreed to, enter into this Agreement.

NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows:

ARTICLE I.

VOTING AGREEMENT; TRANSFER RESTRICTION

1.1. Voting of Company Shares. Not later than two (2) Business Days after the Form S-4 is declared effective by the SEC, each Company Significant Stockholder shall deliver to the Company a written consent in respect of all Company Shares over which such Company Significant Stockholder then has the right to vote or direct the voting in favor of the adoption of the Merger Agreement and the approval of the transactions contemplated by the Merger Agreement (including the Merger) and any other actions presented to the holders of Company Shares (the “Company Stockholders”) that are necessary or desirable to consummate the transactions contemplated by the Merger Agreement (the “Company Stockholder Approval”). In addition, each Company Significant Stockholder agrees that from and after the date hereof, at every meeting of the Company Stockholders, however called, and at every adjournment or postponement thereof (or pursuant to a written consent if the Company Stockholders act by written consent in lieu of a meeting), such Company Significant Stockholders shall, or shall cause the holder of record on any applicable record date to, be present (in person or by proxy) and to vote (or cause to be voted) the Subject Shares over which such Company Significant Stockholder then has the right to vote or direct the voting against (a) any action, proposal, agreement, transaction or proposed transaction that would reasonably be expected to result in a breach in any material respect of any obligation of


(x) the Company, as set forth in the Merger Agreement, or (y) such Company Significant Stockholders, as set forth in this Agreement, or (b) any other action, proposal, agreement or transaction or proposed transaction, in each case, that would reasonably be expected to prevent or materially delay the Merger or any of the other transactions contemplated by the Merger Agreement (other than as expressly contemplated by the Merger Agreement). The obligations of each Company Significant Stockholder specified in this Section 1.1 shall apply during the period from the date of this Agreement until the termination of this Agreement in accordance with its terms, whether or not the Merger or any of the other transactions contemplated by the Merger Agreement is recommended by the Company Board.

1.2. Irrevocable Proxy. Each Company Significant Stockholder hereby irrevocably grants to, and appoints, Parent, the Company and any individual designated in writing by Parent, and each of them individually, as such Company Significant Stockholder’s proxy and attorney-in-fact (with full power of substitution), for and in the name, place and stead of such Company Significant Stockholder’s proxy and attorney-in-fact (with full power of substitution), for and in the name, place and stead of such Company Significant Stockholder, to vote its Subject Shares, or grant a consent or approval in respect of its Subject Shares, in a manner consistent with Section 1.1 if such Company Significant Stockholder has not delivered the written consent contemplated in Section 1.1 within two (2) Business Days after the Form S-4 is declared effective by the SEC. Each Company Significant Stockholder understands and acknowledges that Parent is entering into the Merger Agreement in reliance upon such Company Significant Stockholder’s execution and delivery of this Agreement. Each Company Significant Stockholder affirms that the irrevocable proxy set forth in this Section 1.2 is given in connection with the execution of the Merger Agreement, and that such irrevocable proxy is given to secure the performance of the duties of such Company Significant Stockholder under this Agreement. Each Company Significant Stockholder hereby further affirms that the irrevocable proxy set forth in this Section 1.2 is coupled with an interest and may under no circumstances be revoked. Each Company Significant Stockholder hereby ratifies and confirms all that such irrevocable proxy may lawfully do or cause to be done by virtue hereof. Such irrevocable proxy is executed and intended to be irrevocable in accordance with the provisions of Section 212(e) of the DGCL. Notwithstanding the foregoing, the proxy and appointment granted hereby shall be automatically revoked, without any action by any Company Significant Stockholder, upon any termination of this Agreement pursuant to Section 4.2.

1.3. No Transfer. Except as expressly permitted or required hereunder or under the Merger Agreement, during the period from the date of this Agreement until the termination of this Agreement in accordance with its terms, each Company Significant Stockholder shall not, directly or indirectly, transfer, sell, assign, gift or otherwise dispose of (collectively, “Transfer”) any Subject Shares. Notwithstanding the foregoing, a Company Significant Stockholder may make Transfers of Subject Shares (i) by will or operation of law, (ii) for estate planning purposes or charitable purposes, (iii) to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or is under common control with such Company Significant Stockholder or (iv) if a Company Significant Stockholder is a trust, to any beneficiary of such Company Significant Stockholder or the estate of any such beneficiary; provided that, in each case, the transferee agrees in writing to be bound by the terms and conditions of this Agreement and either such Company Significant Stockholder or the transferee provides Parent and the Company with a copy of such agreement promptly prior to the consummation of any such Transfer; provided, further, that any transferring Company Significant Stockholder shall remain liable for any breaches of this Agreement by such transferee. Upon any such Transfer described in the foregoing sentence, such transferee shall be deemed a “Company Significant Stockholder” hereunder. Any Transfer in violation of the foregoing shall be null and void ab initio.

1.4. Documentation and Information. Each Company Significant Stockholder shall permit and hereby consents to and authorizes the Company, Parent and Merger Sub to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that the Company, Parent or Merger Sub reasonably determines to be necessary in connection with the Merger and any of the transactions contemplated by the Merger Agreement, a copy of this Agreement, such Company Significant Stockholder’s


identity and ownership of Subject Shares and the nature of such Company Significant Stockholder’s commitments and obligations under this Agreement.

1.5. No Exercise of Appraisal Rights. Each Company Significant Stockholder hereby irrevocably and unconditionally waives and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters’ rights and any similar rights (including any notice requirements related thereto) relating to the Merger that such Company Significant Stockholder may have by virtue of, or with respect to, any Company Shares beneficially owned by it immediately prior to the Merger.

1.6. No Solicitation of Transactions. Each Company Significant Stockholder shall not, directly or indirectly: (a) initiate, solicit or knowingly encourage or facilitate any inquiries or the making of any proposal or offer that constitutes, or would reasonably be expected to lead to, any Company Acquisition Proposal; (b) engage in, continue or otherwise participate in any discussions or negotiations regarding, or that would reasonably be expected to lead to, any Company Acquisition Proposal, or (c) provide any nonpublic information or data to any Person in connection with the foregoing, in each case except to the same extent that the Company is permitted to engage in, or take, any of the foregoing activities pursuant to Section 7.2 of the Merger Agreement. Such Company Significant Stockholder hereby represents and warrants that such Company Significant Stockholder has read Section 7.2 of the Merger Agreement and agrees not to facilitate or participate in any actions prohibited thereby.

ARTICLE II.

REPRESENTATIONS AND WARRANTIES OF THE COMPANY SIGNIFICANT STOCKHOLDERS

Each Company Significant Stockholder represents and warrants to each of Parent and the Company that:

2.1. Authorization; Binding Agreement. Such Company Significant Stockholder, if not a natural person, is duly formed, incorporated or organized, validly existing and, to the extent the concept is applicable to such Company Significant Stockholder, in good standing under the laws of its jurisdiction of formation, incorporation or organization. Such Company Significant Stockholder has full power and authority to execute and deliver this Agreement and to perform its obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by such Company Significant Stockholder, and constitutes a legal, valid and binding obligation of such Company Significant Stockholder enforceable against such Company Significant Stockholder in accordance with its terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors’ rights generally or by general principles of equity.

2.2. Ownership of Subject Shares. As of the date hereof, such Company Significant Stockholder is beneficial owner and has the right to vote or direct the voting of the Subject Shares listed on Schedule A opposite the Company Significant Stockholder’s name, free and clear of all Liens that would reasonably be expected to prevent, delay or impair the ability of such Company Significant Stockholder to perform such Company Significant Stockholder’s obligation hereunder, except for any Liens created by this Agreement and restrictions under applicable securities Laws. Such Company Significant Stockholder does not own, of record or beneficially, any shares of capital stock of the Company other than the Subject Shares set forth opposite its name on Schedule A. Such Company Significant Stockholder has the sole right to vote its Subject Shares, and none of such Subject Shares are subject to any voting trust or other agreement, arrangement or restriction with respect to the voting of such Subject Shares, except as contemplated by this Agreement.

2.3. Non-Contravention. The execution and delivery of this Agreement by such Company Significant Stockholder and the performance of the transactions contemplated by this Agreement by such Company Significant Stockholder does not and will not violate, conflict with or result in a breach of: (a) if not a natural person, the organizational documents of such Company Significant Stockholder, (b) any applicable Law or any injunction, judgment, order, decree, ruling, charge, or other restriction of any Governmental Entity to


which such Company Significant Stockholder is subject, or (c) any Contract to which such Company Significant Stockholder is a party or is bound, in each case, that would reasonably be expected to prevent, delay or impair the ability of such Company Significant Stockholder to perform such Company Significant Stockholder’s obligations hereunder.

2.4. Litigation. There is no Proceeding pending or, to the knowledge of such Company Significant Stockholder, any claim that has been asserted against or affecting such Company Significant Stockholder with respect to a Proceeding, nor is there any Order outstanding against such Company Significant Stockholder or to which any of its properties or assets is subject that would, individually or in the aggregate, reasonably be expected to prevent or materially delay or impair the ability of such Company Significant Stockholder to perform its obligations hereunder.

ARTICLE III.

REPRESENTATIONS AND WARRANTIES OF PARENT AND THE COMPANY

Each of Parent and the Company represents and warrants to each of the Company Significant Stockholders that:

3.1. Organization; Authorization. It is a corporation duly incorporated under the Laws of the State of Delaware. The consummation of the transactions contemplated hereby are within its corporate powers and have been duly authorized by all necessary corporate actions on its part; provided that the consummation of the Merger by the Company is subject to the receipt of the Company Stockholder Approval, the Parent Share Issuance is subject to receipt of the Parent Stockholder Approval and the consummation of the Merger by Parent is subject to receipt of the Parent Majority of the Minority Stockholder Approval. It has full power and authority to execute, deliver and perform this Agreement.

3.2. Binding Agreement. This Agreement has been duly authorized, executed and delivered by it and constitutes its valid and binding obligation enforceable against it in accordance with its terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors’ rights generally or by general principles of equity.

ARTICLE IV.

MISCELLANEOUS

4.1. Notices. All notices, requests and other communications to either party hereunder shall be in writing (including electronic mail) and shall be given, (a) if to Parent or the Company, in accordance with the provisions of the Merger Agreement and (b) if to a Company Significant Stockholder, to such Company Significant Stockholder’s address or electronic mail address set forth on a signature page hereto, or to such other address or electronic mail address as such Company Significant Stockholder may hereafter specify in writing to Parent and the Company.

4.2. Termination. This Agreement shall terminate automatically and become void and of no further force or effect, without any notice or other action by any Person, upon the earliest to occur of (a) the termination of the Merger Agreement in accordance with its terms, (b) the Effective Time, (c) any amendment to the Merger Agreement that would materially affect the rights of any Company Significant Stockholder with respect to the Subject Shares without the prior written consent of such Company Significant Stockholder and (d) the mutual written agreement of each Company Significant Stockholder, the Company and Parent. Upon termination of this Agreement, no party shall have any further obligations or liabilities under this Agreement; provided, however, that (i) nothing set forth in this Section 4.2 shall relieve any party from liability for any willful breach of this Agreement prior to termination hereof and (ii) the provisions of this Article IV shall survive any termination of this Agreement.


4.3. Amendments and Waivers. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

4.4. Binding Effect; Benefit; Assignment. The provisions of this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any person other than the parties hereto and their respective successors and assigns. No party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other parties hereto.

4.5. Governing Law; Venue. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to its rules of conflict of laws. Each party hereto hereby irrevocably and unconditionally consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery, or if such court does not have proper jurisdiction, then the federal court of the United States located in the State of Delaware, and appellate courts therefrom (collectively, the “Delaware Courts”) for any litigation arising out of or relating to this Agreement and the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in such courts), waives any objection to the laying of venue of any such litigation in the Delaware Courts and agrees not to plead or claim in any Delaware Court that such litigation brought therein has been brought in any inconvenient forum. Each of the parties hereto agrees that service of process may be made on such party by prepaid certified mail with a proof of mailing receipt validated by the United States Postal Service constituting evidence of valid service. Service made pursuant to the foregoing shall have the same legal force and effect as if served upon such party personally within the State of Delaware. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.

4.6. Counterparts. The parties may execute this Agreement in one or more counterparts, each of which will be deemed an original and all of which, when taken together, will be deemed to constitute one and the same agreement. Any signature page hereto delivered by facsimile machine or by e-mail (including in portable document format (pdf), electronic signature, or otherwise) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto and may be used in lieu of the original signatures for all purposes. Each party that delivers such a signature page agrees to later deliver an original counterpart to any other party that requests it.

4.7. Entire Agreement. This Agreement (together with the Merger Agreement, to the extent referred to in this Agreement) constitutes the entire agreement between the parties with respect to the subject matter of this Agreement and supersedes all prior agreements and understandings, both oral and written, between the parties with respect to its subject matter.

4.8. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other Governmental Entity to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to either party. Upon such a determination, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.


4.9. Specific Performance. The parties hereto agree that Parent and the Company would be irreparably damaged if for any reason any Company Significant Stockholder fails to perform any of its obligations under this Agreement and that Parent and the Company may not have an adequate remedy at law for money damages in such event. Accordingly, each of Parent and the Company shall be entitled to specific performance and injunctive and other equitable relief to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof in any Delaware Court, in addition to any other remedy to which it is entitled at law or in equity, in each case without posting bond or other security, and without the necessity of proving actual damages.

4.10. Remedies Cumulative. Except as otherwise provided herein, the rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder.

4.11. Headings. The Section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.

4.12. No Presumption. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting or causing any instrument to be drafted.

4.13. Further Assurances. Each of the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement.

4.14. Interpretation. Unless the context otherwise requires, as used in this Agreement: (a) “or” is not exclusive; (b) “including” and its variants mean “including, without limitation” and its variants; (c) words defined in the singular have the parallel meaning in the plural and vice versa; (d) words of one gender shall be construed to apply to each gender; and (e) the terms “Article,” “Section” and “Schedule” refer to the specified Article, Section or Schedule of or to this Agreement.

4.15. Capacity as Company Significant Stockholder. Each Company Significant Stockholder signs this Agreement solely in such Company Significant Stockholder’s capacity as a holder of Company Shares, and not in such Company Significant Stockholder’s capacity as a director, officer or employee of the Company. Notwithstanding anything herein to the contrary, nothing herein shall in any way restrict a director or officer of the Company in the exercise of his or her fiduciary duties as a director or officer of the Company, or prevent or be construed to create any obligation on the part of any director or officer of the Company from taking any action in his or her capacity as such director or officer.

4.16. Registration Rights. Parent agrees and acknowledges that all Parent Shares issued to the Company Significant Stockholders pursuant to the Merger (and any capital stock issued or issuable with respect to such Parent Shares, including, without limitation, (1) as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock into which such Parent Shares are converted or exchanged and shares of capital stock of any other entity into which such Parent Shares are converted or exchanged) shall constitute “Registrable Securities” and “Piggyback Registrable Securities” for purposes of, and be subject to the registration rights under, the Registration Rights Agreement, dated as of December 23, 2014, by and among Parent and Cambridge Equities LP (the “Registration Rights Agreement”). In addition, the Company agrees that, from and after the Effective Time, the reference to “one (1)” in Section 2(a)(iii)(1) of the Registration Rights Agreement shall be replaced with “seven (7).”

4.17. Special Committee. Notwithstanding anything to the contrary set forth in this Agreement, until the termination of this Agreement pursuant to Section 4.2, (i) Parent may take the following actions only with the prior approval of the Special Committee: (a) amending, restating, modifying or otherwise changing any


provision of this Agreement; (b) waiving any right under this Agreement or extending the time for the performance of any obligation of any Company Significant Stockholder hereunder; (c) terminating this Agreement; (d) making any decision or determination, or taking any action under or with respect to this Agreement or the transactions contemplated hereby that would reasonably be expected to be, or is required to be, approved, authorized, ratified or adopted by the Parent Board; and (e) agreeing to do any of the foregoing and (ii) no decision or determination shall be made, or action taken, by Parent or the Parent Board under or with respect to this Agreement or the transactions contemplated hereby without first obtaining the approval of the Special Committee. For the avoidance of doubt, any requirement of Parent or the Parent Board to obtain the approval of the Special Committee pursuant to this Section 4.17 shall not, and shall not be deemed to, modify or otherwise affect any rights of any Company Significant Stockholder, or any obligations of Parent, the Special Committee or the Parent Board to any Company Significant Stockholder set forth in this Agreement.

4.18. No Agreement Until Executed. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until this Agreement is executed by all parties hereto.

[SIGNATURE PAGES FOLLOW]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.

 

NANTKWEST, INC.
By:  

/s/ Richard Adcock

  Name: Richard Adcock
  Title: Chief Executive Officer

[SIGNATURE PAGE TO COMPANY VOTING AGREEMENT]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.

 

IMMUNITYBIO, INC.
By:  

/s/ Patrick Soon-Shiong

  Name: Patrick Soon-Shiong, MBBCh, FRCS(C), FACS
  Title: Chairman and Chief Executive Officer

[SIGNATURE PAGE TO COMPANY VOTING AGREEMENT]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.

 

CAMBRIDGE EQUITIES, LP
By: MP 13 Ventures, LLC, its General Partner
By:  

/s/ Charles Kenworthy

  Name: Charles Kenworthy
  Title: Manager

[SIGNATURE PAGE TO COMPANY VOTING AGREEMENT]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.

 

NANTBIO, INC.
By:  

/s/ Charles Kim

  Name: Charles Kim
  Title: General Counsel

[SIGNATURE PAGE TO COMPANY VOTING AGREEMENT]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.

 

CALIFORNIA CAPITAL EQUITY LLC
By:  

/s/ Charles Kenworthy

  Name: Charles Kenworthy
  Title: Manager

[SIGNATURE PAGE TO COMPANY VOTING AGREEMENT]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.

 

DR. PATRICK SOON-SHIONG

/s/ Patrick Soon-Shiong

Dr. Patrick Soon-Shiong

[SIGNATURE PAGE TO COMPANY VOTING AGREEMENT]


Schedule A

 

Name of Company Significant Stockholder

   No. of Subject
Shares
 

Cambridge Equities, LP

     270,000,000  

NantBio, Inc.

     10,236,159  

California Capital Equity LLC

     9,738,900  

Dr. Patrick Soon-Shiong

      6,988,013 1 

 

1 

NantWorks, LLC, an Affiliate of Dr. Patrick Soon-Shiong, is a party to the Company Warrant, pursuant to which the Company issued NantWorks, LLC a warrant to purchase 2,000,000 Company Shares.